ABCL - Abcellera Biologics - Stock Forecast

Healthcare - Sector

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ABCL is currently covered by 4 analysts with an average price target of $14.98. This is a potential upside of $10.69 (249.18%) from yesterday's end of day stock price of $4.29.

Abcellera Biologics 's activity chart (see below) currently has 41 price targets and 44 ratings on display. The stock rating distribution of ABCL is 77.78% BUY and 22.22% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 18.88% with an average time for these price targets to be met of 87.29 days.

Highest price target for ABCL is $10, Lowest price target is $5, average price target is $7.5.

Most recent stock forecast was given by SCOTT SCHOENHAUS from KEYBANK on 14-Jul-2025. First documented stock forecast 05-Jan-2021.

Best performing analysts who are covering ABCL - Abcellera Biologics :

Puneet Souda Scott Schoenhaus Do Kim Tiago Fauth Gary Nachman Andrea Tan Robert Wasserman

Currently out of the existing stock ratings of ABCL, 14 are a BUY (77.78%), 4 are a HOLD (22.22%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Scott Schoenhaus (KEYBANK)

Buy

$10

$5.41 (117.86%)

1 months 5 days ago
(14-Jul-2025)

3/7 (42.86%)

$5.76 (135.85%)

217

Please subscribe to see the analyst performance score

Robert Wasserman (BENCHMARK)

Hold

5 months 16 days ago
(03-Mar-2025)

0/2 (0%)

$6.55 (120.18%)

Please subscribe to see the analyst performance score

Gary Nachman (RAYMOND JAMES)

Buy

$0.41 (8.93%)

$22

9 months 14 days ago
(05-Nov-2024)

1/4 (25%)

$2.28 (83.82%)

258

Please subscribe to see the analyst performance score

Andrea Tan (GOLDMAN SACHS)

Buy

$24

$19.41 (422.88%)

$30

2 years 15 days ago
(04-Aug-2023)

0/2 (0%)

$17.96 (297.35%)

Please subscribe to see the analyst performance score

Tiago Fauth (WELLS FARGO)

Buy

$28

$23.41 (510.02%)

$34

2 years 3 months 14 days ago
(05-May-2023)

1/6 (16.67%)

$22.01 (367.45%)

Please subscribe to see the analyst performance score

Show more analysts

Load Price Targets and Ratings Chart

To gain access for the analyst/ stock price target chart please use a computer

What is ABCL (Abcellera Biologics ) average time for price targets to be met?

On average it took 87.29 days on average for the stock forecasts to be realized with a an average price target met ratio 18.88

Which analyst has the current highest performing score on ABCL (Abcellera Biologics ) with a proven track record?

PUNEET SOUDA

Which analyst has the current lower performing score on ABCL (Abcellera Biologics ) with a proven track record?

ROBERT WASSERMAN

Which analyst has the most public recommendations on ABCL (Abcellera Biologics )?

Puneet Souda works at LEERINK and has 19 price targets and 10 ratings on ABCL

Which analyst is the currently most bullish on ABCL (Abcellera Biologics )?

Tiago Fauth with highest potential upside - $23.41

Which analyst is the currently most reserved on ABCL (Abcellera Biologics )?

Robert Wasserman with lowest potential downside - -$0

Abcellera Biologics in the News

AbCellera signals clinical-stage transition with first patient dosing for ABCL635 and targets mid-2026 data milestone

Earnings Call Insights: AbCellera Biologics Inc. (ABCL) Q2 2025 MANAGEMENT VIEW * CEO Carl L.G. Hansen announced, “This quarter, we achieved a major company milestone, receiving Health Canada authorization to initiate AbCellera’s first 2 clinical trials for ABCL635 and ABCL575. Today, I’m pleased to announce that dosing has begun in our Phase I clinical trial...

Curious about the stocks that are showing activity after the closing bell on Thursday?

Wondering what’s happening in today’s after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] GAINERS TICKER CHANGE COMMENT MRM [https://www.chartmill.com/stock/quote/MRM/profile] 56.67% MEDIROM HEALTHCARE TECHNOLOG (NASDAQ:MRM [https://www.chartmill.com/stock/quote/MRM/profile]) exhibits strong performance after hours, with shares rising 56.67% to $1.88 during Thursday’s after-hours session. Earlier today the company had a press release: MEDIROM Joins the...